Pegargiminase: all 37 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)Not yet recruitingNCT07389278Phase 1/2
• Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)RecruitingNCT06085729Phase 1/2
• Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular CarcinomaRecruitingNCT06034977Phase 2
• Study of ADI-PEG 20 Versus Placebo in Subjects With NASHRecruitingNCT05842512Phase 2
• Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular CarcinomaRecruitingNCT05317819Phase 3
• A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingNCT03970447Phase 2/3
• ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung CancerCompletedNCT03449901Phase 2Results posted
• Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung CancerTerminatedNCT01266018Phase 2Results posted
• Study of ADI-PEG 20 in Patients With Advanced MelanomaCompletedNCT00520299Phase 1/2Results posted
• Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by SurgeryCompletedNCT00450372Phase 2Results posted
• A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaWithdrawnNCT06006286Phase 1/2
• ADI-PEG20, Obesity and PrediabetesWithdrawnNCT05829239Phase 2
• Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue SarcomaTerminatedNCT05813327Phase 1
• Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)TerminatedNCT05712694Phase 3
• ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung CancersTerminatedNCT05616624Phase 1/2
• Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid LeukemiaActive, not recruitingNCT05001828Phase 1
• Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver CancerWithdrawnNCT04965714Phase 2
• ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeActive, not recruitingNCT04587830Phase 2
• Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaCompletedNCT03922880Phase 1
• Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and CarboplatinWithdrawnNCT03498222Phase 1
• Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid CancersTerminatedNCT03254732Phase 1
• Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AMLTerminatedNCT02875093Phase 1
• Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular CarcinomaTerminatedNCT02102022Phase 1/2
• Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver CancerCompletedNCT02101593Phase 1
• Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic CancerCompletedNCT02101580Phase 1
• Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and CisplatinTerminatedNCT02029690Phase 1
• Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT02006030Phase 2
• Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast CancerCompletedNCT01948843Phase 1
• PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic TherapyCompletedNCT01910025Phase 2
• PH 2 ADI-PEG 20 Acute Myeloid LeukemiaCompletedNCT01910012Phase 2
• Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic MelanomaCompletedNCT01665183Phase 1
• Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) DeficientCompletedNCT01528384Phase 1
• Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung CancerCompletedNCT01497925Phase 1
• Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic TherapyCompletedNCT01287585Phase 3
• A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural MesotheliomaStatus unknownNCT01279967Phase 2
• Testing of ADI-PEG in Hepatocellular CarcinomaCompletedNCT00056992Phase 2
• ADI-PEG in Patients With Metastatic MelanomaCompletedNCT00029900Phase 1

← Pegargiminase overview